Financial Performance - Boji Medical Technology Co., Ltd. reported a revenue of RMB 500 million for the fiscal year 2024, representing a 20% increase compared to RMB 416.67 million in 2023[20]. - The company's operating revenue for 2024 reached ¥742,019,124.54, representing a 33.50% increase compared to ¥555,832,418.60 in 2023[5]. - The net profit attributable to shareholders for 2024 was ¥28,776,806.52, an 18.23% increase from ¥24,339,436.55 in 2023[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses surged by 92.71% to ¥19,304,628.89 from ¥10,017,432.95 in 2023[5]. - The company anticipates a net profit margin of 10% for 2024, compared to 8% in 2023, driven by operational efficiencies[20]. - The company reported a total investment of ¥44,125,000.00 during the reporting period, representing a substantial increase of 186.48% compared to ¥15,402,616.00 in the previous year[85]. - The company achieved a gross profit margin of 64.64% for the reported period[93]. Dividend Distribution - The company plans to distribute a cash dividend of 0.12 yuan per 10 shares to all shareholders, based on a total of 380,503,928 shares[8]. - The cash dividend represents 100% of the total distributable profit of RMB 28,776,806.52 for the year[154]. - For the year 2024, the company proposes a cash dividend of RMB 0.12 per 10 shares, with a total expected payout of RMB 4,566,047.14[156]. Business Expansion and Strategy - The company aims to expand its market presence by launching three new drug candidates in 2024, targeting a market size of approximately RMB 1 billion[20]. - The company is expanding its business into preclinical research and CDMO services, facing potential risks due to competition and lack of experience in these areas[8]. - The company is pursuing strategic acquisitions to bolster its capabilities, with a target of completing two acquisitions by the end of 2024[20]. - The company is focused on enhancing its digital health solutions, aiming for a 50% increase in user engagement through its online platforms in 2024[20]. - The company is committed to increasing its market share in the CDMO sector by improving order fulfillment capabilities and reducing delivery cycles, targeting rapid revenue growth from commercialized products[108]. Research and Development - The company has allocated RMB 100 million for research and development of new technologies and products in 2024, a 25% increase from RMB 80 million in 2023[20]. - The company has developed a one-stop service platform for preclinical research, significantly enhancing its capabilities in pharmacology and toxicology evaluations[49]. - The company has achieved GLP certification for its non-clinical evaluation services, covering various therapeutic areas, including cardiovascular and oncology drugs[52]. - The company is developing a long-acting nano-crystal technology platform aimed at improving drug delivery and reducing administration frequency, which is anticipated to create new business growth points[71]. - The company has completed the development of a new formulation of berberine for children, which is easier to administer[73]. Risk Management - The company acknowledges the risk of contract execution delays due to the complex nature of new drug development, which may lead to increased operational costs[5]. - The company emphasizes the importance of internal management and integration to mitigate risks associated with its expanding operational scale and business scope[8]. - The company recognizes the volatility of drug approval policies in China, which could impact its R&D investments and revenue[4]. - The company has established specific responsibility-sharing models in contracts to address potential delays and associated penalties[6]. Market Competition - The company faces increased market competition from domestic CRO companies, necessitating higher marketing and service standards[7]. - The Chinese CRO industry is expected to maintain a CAGR of 14%-16% from 2024 to 2026, with the market size projected to reach ¥478 billion in 2024[32]. - The company anticipates strong demand for outsourced clinical research services due to increasing complexity in drug development and stricter regulatory requirements[33]. Governance and Compliance - The company maintains independence from its controlling shareholder in terms of business, personnel, assets, and finance[118]. - The board of directors consists of 7 members, including 3 independent directors, complying with legal and regulatory requirements[114]. - The company has a dedicated financial department and independent financial decision-making capabilities[118]. - The company has not faced any disciplinary actions from regulatory bodies regarding internal control issues during the reporting period[117]. - The company ensures timely and accurate information disclosure through designated platforms and publications[115]. Environmental Responsibility - The company has obtained a wastewater discharge permit valid until October 31, 2027[187]. - The wastewater treatment facility has a capacity of 120m³/d and employs a "flocculation sedimentation + iron-carbon micro-electrolysis" process[189]. - The company reported a total wastewater discharge of 0.33 tons for CODcr, which is below the regulatory limit of 0.412 tons per annum[188]. - The company has established solid waste management records to ensure compliance with environmental regulations[192]. Employee Management - The company had a total of 1,169 employees at the end of the reporting period, with 888 being technical personnel, representing approximately 76% of the workforce[148]. - The company has a comprehensive training system that includes various training categories, ensuring continuous development of employee skills and capabilities[151]. - The company has implemented a differentiated compensation policy based on department, position, and job nature, aiming for performance-oriented salary management[150]. Future Outlook - The company plans to continue expanding its market presence and enhancing product development strategies[1]. - Future outlook includes potential adjustments in management structure following the resignation of certain executives in 2025[140]. - The company is exploring potential mergers and acquisitions to enhance its competitive position in the market[134].

博济医药（300404）公告，2025年第一季度营业收入1.39亿元，同比下降17.06%。净利润390.06万元， 同比下降76.38%。 ...

Core Insights - Boji Pharmaceutical's stock closed at 9.15 yuan, up 2.58%, with a rolling PE ratio of 78.60 times and a total market capitalization of 3.505 billion yuan [1] - The average PE ratio for the medical services industry is 46.70 times, with a median of 48.76 times, placing Boji Pharmaceutical at the 34th position in the industry ranking [1] - As of September 30, 2024, the number of shareholders for Boji Pharmaceutical is 22,995, a decrease of 4,424 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] Company Overview - Boji Pharmaceutical Co., Ltd. primarily provides comprehensive "one-stop" CRO services for domestic and international pharmaceutical companies and research institutions, including clinical research services, preclinical research services, CDMO services, consulting services, independent preclinical R&D, and technology transfer services [1] - The company has received several accolades, including being ranked 8th in the "Top 20 Chinese Pharmaceutical CRO Companies 2024," recognized in the "Top 50 Chinese Pharmaceutical R&D Companies 2023," and awarded the "Excellence Achievement Award" for being a high-tech enterprise for 15 consecutive years [1] Financial Performance - In the latest quarterly report for 2024, Boji Pharmaceutical achieved a revenue of 555.6 million yuan, representing a year-on-year increase of 55.01%, and a net profit of 43.2778 million yuan, reflecting a year-on-year growth of 87.98%, with a gross profit margin of 32.19% [1]

2024 年 8 月 23 日，博济医药科技股份有限公司（以下简称"公司"）召开 第五届董事会第十次会议和第五届监事会第十次会议，审议通过了《关于使用暂 时闲置募集资金进行现金管理的议案》，同意公司及子公司使用不超过人民币 0.6 亿元（含）闲置募集资金进行现金管理，有效期自董事会审议通过之日起 12 个 月内，在前述额度和期限范围内可循环滚动使用。具体内容详见公司于 2024 年 8 月 27 日在巨潮资讯网（http://www.cninfo.com.cn/）上发布的《关于使用暂时闲 置募集资金进行现金管理的公告》（公告编号：2024-087）。 近日，公司全资子公司深圳博瑞医药科技有限公司（以下简称"深圳博瑞"） 在授权范围内使用闲置募集资金购买的理财产品已到期赎回。现就有关进展情况 公告如下： 证券代码：300404 证券简称：博济医药 公告编号：2025-018 博济医药科技股份有限公司 关于使用暂时闲置募集资金进行现金管理到期赎回的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 | | | 中国工商银 | 中国工商银行挂钩汇率法 | | | ...

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Boji Pharmaceutical, which has a current stock price of 9.1 yuan and a rolling PE ratio of 78.17 times, significantly higher than the industry average of 46.29 times [1][2] - Boji Pharmaceutical's total market capitalization is 3.486 billion yuan, ranking 35th in the medical services industry based on PE ratio [1][2] - As of the third quarter of 2024, 51 institutions hold shares in Boji Pharmaceutical, with a total of 2.6617 million shares valued at 0.023 billion yuan [1] Group 2 - The company specializes in providing comprehensive CRO services for pharmaceutical companies and research institutions, including clinical research, preclinical research, CDMO services, and technology transfer [1] - Boji Pharmaceutical has received several accolades, including being ranked 8th among the top 20 CRO companies in China for 2024 and recognized as one of the top 50 pharmaceutical R&D companies in 2023 [1] - The latest financial results for the third quarter of 2024 show that the company achieved a revenue of 0.556 billion yuan, representing a year-on-year increase of 55.01%, and a net profit of 43.2778 million yuan, up 87.98% year-on-year, with a gross profit margin of 32.19% [1]

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 证券代码：300404 证券简称：博济医药 公告编号：2025-017 博济医药科技股份有限公司 关于使用暂时闲置募集资金进行现金管理到期赎回的公告 1 2024 年 8 月 23 日，博济医药科技股份有限公司（以下简称"公司"）召开 第五届董事会第十次会议和第五届监事会第十次会议，审议通过了《关于使用暂 时闲置募集资金进行现金管理的议案》，同意公司及子公司使用不超过人民币 0.6 亿元（含）闲置募集资金进行现金管理，有效期自董事会审议通过之日起 12 个 月内，在前述额度和期限范围内可循环滚动使用。具体内容详见公司于 2024 年 8 月 27 日在巨潮资讯网（http://www.cninfo.com.cn/）上发布的《关于使用暂时闲 置募集资金进行现金管理的公告》（公告编号：2024-087）。 近日，公司在授权范围内使用闲置募集资金购买的理财产品已到期赎回。现 就有关进展情况公告如下： 二、 截至本公告日前十二个月内使用闲置募集资金购买理财产品的情况 | 序 | 委托方 | 受托方 | 产品名称 | 产品 ...

专利申请日：2024 年 07 月 29 日 授权公告日：2025 年 04 月 08 日 本发明属于生物医学检测技术领域，具体涉及一种检测人源细胞在动物体内 分布的方法及检测产品。本发明公开的检测方法简单快速、特异性好、灵敏度高、 检测范围宽，可用来示踪动物体内植入的人源细胞的定向分布，可以实现短时间 内处理大量的样本，为干细胞产品的遴选提供数据支持。 证券代码：300404 证券简称：博济医药 公告编号：2025-016 博济医药科技股份有限公司 关于公司获得发明专利证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，博济医药科技股份有限公司（以下简称"公司"）获得国家知识产权 局颁发的一项发明专利证书，具体情况如下： 发明名称：一种检测人源细胞在动物体内分布的方法及检测产品 专 利权人 ：博济医药科技股份有限公司 证书号：第 7859104 号 专利号：ZL 2024 1 1018741.2 该专利的获得对公司经营业绩不会产生重大影响，但有利于公司的技术创新， 完善知识产权保护体系，充分发挥公司的自主知识产权优势，形成持续创新机制， 提升公 ...

Group 1 - The core viewpoint of the article highlights the significant decline in the stock price of Boji Pharmaceutical, which closed at 8.27 yuan, down 19.47%, with a rolling PE ratio of 71.04 times and a total market value of 3.168 billion yuan [1] - Boji Pharmaceutical ranks 35th in the medical services industry, which has an average PE ratio of 45.72 times and a median of 41.83 times [1] - As of September 30, 2024, the number of shareholders in Boji Pharmaceutical decreased by 4,424 to 22,995, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Group 2 - Boji Pharmaceutical primarily provides comprehensive "one-stop" CRO services for domestic and international pharmaceutical companies and research institutions, including clinical research services, preclinical research services, CDMO services, and technology transfer services [1] - The company has received several accolades, including being ranked 8th among the "Top 20 Chinese Pharmaceutical CROs in 2024" and recognized as a "Top 50 Chinese Pharmaceutical R&D Company in 2023" [1] - In the latest financial report for Q3 2024, Boji Pharmaceutical achieved a revenue of 555.6 million yuan, representing a year-on-year increase of 55.01%, and a net profit of 43.28 million yuan, up 87.98%, with a gross profit margin of 32.19% [1]

Summary of the Conference Call Company and Industry - **Company**: 博济医药 (Boji Pharmaceutical) - **Industry**: Hepatitis B treatment and research Key Points and Arguments Research and Development Progress - In 2024, Boji Pharmaceutical made significant advancements in the research for functional cure of Hepatitis B, optimizing its pipeline by terminating or pausing some projects to focus on clinical research for Hepatitis B functional cure [3][5] - The company has three core candidates in its Hepatitis B pipeline: V179, psi, and tobia_bar_antibody, which are expected to achieve higher rates of functional cure through various combinations [3][5] - The Elexxion study revealed that siRNA combined with long-acting interferon significantly improves the functional cure rate compared to long-acting interferon alone, with data showing a notable increase in Hepatitis B surface antigen clearance rates [3][8] - The 2BT study evaluated a three-drug combination therapy aimed at maximizing functional cure rates, confirming the strategy of combination therapy and guiding registration pathway decisions [3][9] Financial Status - As of December 31, 2024, the company had over 2.4 billion RMB in cash and cash equivalents, sufficient to support operations until after 2028 [3][16] - R&D expenses decreased by 38% from 400 million RMB in 2023 to 250 million RMB in 2024, reflecting a focus on pipeline optimization [3][16] Market Strategy - In China, Boji Pharmaceutical focuses on developing three Hepatitis B assets recognized as breakthrough therapies by the CDE, targeting the largest Hepatitis B patient population globally [3][7] - The company collaborates with Lear to obtain fast track and breakthrough therapy designations from the FDA for HDV treatment, as well as orphan drug designations from the EMA [3][7] Clinical Trials and Future Plans - The company plans to initiate Phase III clinical trials in 2026, aiming for optimized functional cure outcomes [3][25] - Key milestones to watch for in 2025 include data from imaging studies and ongoing clinical trials, which will inform future development and registration pathways [3][14] Unique Drug Mechanisms and Patent Protection - V179 is a recombinant protein vaccine that induces strong immune responses, while psi is an siRNA and tobia_bar_antibody is a comprehensive antibody, each with unique mechanisms [3][5][19] - The company has extensive patent protection for its Hepatitis B candidates, with B179's patent expected to last until 2040 [3][19] Long-term Strategy - Boji Pharmaceutical aims to optimize its organizational structure and control operational costs while focusing on advancing Hepatitis B projects and seeking partnerships for other potential candidates [3][18] - The company is committed to creating long-term value for shareholders by expanding treatment options and patient accessibility through innovative therapies [3][18] Commercialization Strategy - The company is considering various commercialization strategies, including partnerships and direct market expansion in key cities, to enhance its market development capabilities [3][30] - Future commercialization plans will be based on the results of Phase III clinical trials [3][29] Additional Insights - The company is actively seeking partnerships to advance non-HBV projects, including those targeting multi-drug resistant infections and HIV therapies [3][6][17] - The focus remains on Hepatitis B cure research, with a commitment to not deviate from this core mission [3][32]

证券代码：300404 证券简称：博济医药 公告编号：2025-015 博济医药科技股份有限公司 关于公司获得发明专利证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，博济医药科技股份有限公司（以下简称"公司"）获得国家知识产权 局颁发的一项发明专利证书，具体情况如下： 发明名称：西红花酸钠的制备方法 专利号：ZL 2021 1 1247573.0 专利申请日：2021 年 10 月 26 日 授权公告日：2025 年 03 月 28 日 本发明属于天然药物化学技术领域，涉及天然植物活性成分提取分离技术领 域，具体涉及一种西红花酸钠的制备方法。本制备工艺操作步骤较为简单，生产 周期短，制备工艺路线稳定，在制备过程中，西红花酸进一步处理得到了西红花 酸钠，进而显著提高了其生物利用度。 该专利的获得对公司经营业绩不会产生重大影响，但有利于公司的技术创新， 完善知识产权保护体系，充分发挥公司的自主知识产权优势，形成持续创新机制， 提升公司核心竞争力。 特此公告。 博济医药科技股份有限公司董事会 专 利权人 ：博济医药科技股份有限公司 证书号：第 78 ...